Expression of TBX3 in Hepatocellular Carcinoma and Its Clinical Implication

Abstract

BackgroundHepatocellular carcinoma (HCC) is the fifth most common malignancy in China, and China’s annual number of new cases accounts for about 45% of the world total. This research was aimed to study the expression of TBX3 protein in HCC and exploring its clinical significance.Material/MethodsWe collected tumor tissues and adjacent non-tumoral tissues of 174 patients with HCC undergoing surgical resection. The expression of TBX3 protein in different tissues and cell lines in vitro (LO2, HHL-5, MHC97-L, MHC97-H) was detected by immunohistochemistry or Western blotting, and the relationship between TBX3 expression and clinical data of patients with HCC was analyzed.ResultsThe expression of TBX3 protein in HCC was significantly correlated with histological grade, tumor size, cancer cell metastasis, hepatitis B surface antigen, and the expression of Ki-67 in tumor tissues (P<0.05), and it was positively correlated with serum AFP level (r=0.766, P<0.05). The expression of TBX3 increased with increased histological grade in HCC (P<0.05). Cox regression analysis showed that the expression of TBX3 protein in HCC was an independent risk factor for prognosis (OR=0.524, 95% CI=0.283–0.964). The 5-year survival rate of patients with HCC that highly expressed TBX3 protein was 20.83%, which was significantly lower than the 40.20% rate in patients with low expression (P<0.05).ConclusionsThe expression of TBX3 in HCC patients undergoing surgical resection is high, and its expression increases with the degree of tumor differentiation. It is related to the metastasis of tumor cells and is positively correlated with the serum level of AFP and may affect the survival time of HCC patients undergoing surgical resection.

The roles and regulation of TBX3 in development and disease

“…Furthermore, TBX3 promotes chondrosarcoma cell proliferation by directly binding to and repressing the p21 WAF1/CIP1 promoter at a T-element at −121 bp (Willmer et al, 2016a(Willmer et al, , 2016b. More recently, TBX3 was shown to promote proliferation of papillary thyroid carcinoma cells through repressing p57 KIP2 (Li et al, 2018a(Li et al, , 2018b. This resulted from TBX3 binding and recruiting the PRC2 and HDACs 1 and 2 to the region of the CDKN1C promoter that regulates p57 KIP2 expression.…”

Asiaticoside Antagonizes Proliferation and Chemotherapeutic Drug Resistance in Hepatocellular Carcinoma (HCC) Cells

“…Hepatocellular carcinoma (HCC), a heterogeneous group of diseases, is the sixth most common cancer worldwide, causing about 60 000 deaths per year [ 1 ]. In China, HCC is the fifth most commonly diagnosed cancer after lung cancer, gastric cancer, esophageal cancer, and breast cancer, and it has a high mortality rate [ 2 ]. A series of novel therapeutic strategies are now available for HCC, including surgical resection and liver transplantation, which have become primary surgical treatment strategies for HCC [ 3 ]; however the 5-year survival rate after surgery is still only 15–40% [ 4 – 6 ].…”

The effect of dietary phytochemicals on nuclear factor erythroid 2-related factor 2 (Nrf2) activation: a systematic review of human intervention trials

“…It has been shown that Nrf2 activation declines with age [ 90 , 91 ] and is downregulated in diseases such as type 2 diabetes [ 92 ] and atherosclerosis [ 93 ]. In view of this, it could be speculated that older, diseased individuals are more likely to benefit from an intervention attempting to reestablish Nrf2 activation than young, healthy individuals, in whom Nrf2 activation is unlikely to be impaired.…”